Back to Resource Hub White paper

Maintaining Precision of Evaluations in Medical Trials During COVID-19

Signant’s Anthony Everhart discusses that when it comes to maintaining accuracy and precision in clinical trials during the pandemic, it’s important to consider endpoint data and methods for validity.

In general, there are two primary approaches: simplification and modification. The white paper details the three key considerations with simplification: Determine endpoint data risks Modify the protocol to collect less data Consult with the right committees.

The paper argues that rapid modernization and decentralization of clinical trials should become more of the norm even beyond COVID-19.

Similar posts

Looking for more insights? Explore related resources.

WHITE PAPER

Takeaways and Perspectives: FDA Draft Guidance on DCTs

READ THE PAPER
BLOG POST

Approaches to Assessing Clinical Endpoint Data

VISIT THE BLOG
ARTICLE

The Changing Face of Oncology Endpoint Monitoring

READ THE PAPER

Get notified on new marketing insights

Here mention the benefits of subscribing